Enanta Pharmaceuticals ENTA announced today that new
Phase 2b data related to ABT-450, Enanta's lead HCV protease inhibitor
identified in its ongoing collaboration with AbbVie, as well as new
preclinical data on Enanta's proprietary cyclophilin inhibitor, EDP-546,
will be presented at the International Liver Congress, (ILC), which is
the 48th Annual Meeting of the European Association for the
Study of the Liver (EASL) taking place in Amsterdam April 24-28, 2013.
Results from "Aviator," AbbVie's Phase 2b clinical trial of ABT-450
combined with two of AbbVie's proprietary investigational direct-acting
antivirals (DAAs), for the treatment of hepatitis C
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in